JP2018536002A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536002A5
JP2018536002A5 JP2018528691A JP2018528691A JP2018536002A5 JP 2018536002 A5 JP2018536002 A5 JP 2018536002A5 JP 2018528691 A JP2018528691 A JP 2018528691A JP 2018528691 A JP2018528691 A JP 2018528691A JP 2018536002 A5 JP2018536002 A5 JP 2018536002A5
Authority
JP
Japan
Prior art keywords
vaccine composition
domain
mic
fusion protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018528691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536002A (ja
JP7099956B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/064969 external-priority patent/WO2017096374A1/en
Publication of JP2018536002A publication Critical patent/JP2018536002A/ja
Publication of JP2018536002A5 publication Critical patent/JP2018536002A5/ja
Priority to JP2022105405A priority Critical patent/JP7564842B2/ja
Application granted granted Critical
Publication of JP7099956B2 publication Critical patent/JP7099956B2/ja
Priority to JP2024167997A priority patent/JP2024177207A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018528691A 2015-12-04 2016-12-05 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種 Active JP7099956B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022105405A JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US62/263,377 2015-12-04
US201662422454P 2016-11-15 2016-11-15
US62/422,454 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105405A Division JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Publications (3)

Publication Number Publication Date
JP2018536002A JP2018536002A (ja) 2018-12-06
JP2018536002A5 true JP2018536002A5 (enExample) 2020-01-16
JP7099956B2 JP7099956B2 (ja) 2022-07-12

Family

ID=57590885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018528691A Active JP7099956B2 (ja) 2015-12-04 2016-12-05 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2022105405A Active JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A Pending JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022105405A Active JP7564842B2 (ja) 2015-12-04 2022-06-30 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種
JP2024167997A Pending JP2024177207A (ja) 2015-12-04 2024-09-27 がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種

Country Status (24)

Country Link
US (3) US10993971B2 (enExample)
EP (1) EP3383426A1 (enExample)
JP (3) JP7099956B2 (enExample)
KR (1) KR20180088458A (enExample)
CN (1) CN108770343A (enExample)
AU (3) AU2016362597C1 (enExample)
BR (1) BR112018010705A8 (enExample)
CA (1) CA3005910A1 (enExample)
CL (3) CL2018001470A1 (enExample)
CO (1) CO2018006642A2 (enExample)
CR (2) CR20180350A (enExample)
CU (2) CU20210061A7 (enExample)
EA (1) EA201891287A1 (enExample)
IL (1) IL259490A (enExample)
MX (2) MX2018006785A (enExample)
MY (1) MY199248A (enExample)
NZ (1) NZ742663A (enExample)
PE (2) PE20230495A1 (enExample)
PH (1) PH12018501170A1 (enExample)
RU (2) RU2747296C2 (enExample)
SG (1) SG11201804597TA (enExample)
TN (1) TN2018000187A1 (enExample)
WO (1) WO2017096374A1 (enExample)
ZA (1) ZA202204223B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
MX2020010199A (es) 2018-04-03 2021-01-08 Sanofi Sa Polipeptidos antigenicos del virus sincitial respiratorio.
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
WO2024222886A1 (zh) * 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE60043930D1 (de) 1999-03-19 2010-04-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
ATE396739T1 (de) 2001-10-01 2008-06-15 Us Health Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
CN105566497A (zh) 2002-05-10 2016-05-11 新世纪药品有限公司 融合铁蛋白在疫苗和其他方面的应用
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2665090A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US20120269721A1 (en) 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
EP2514718A4 (en) 2009-12-18 2013-09-04 Kao Corp METHOD FOR PRODUCING MESOPOROUS SILICONE ARTICLES
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
KR20140069222A (ko) * 2011-09-23 2014-06-09 유니버시티 오브 오슬로 교차 제시 수지상 세포를 표적으로 하는 백시바디
ES2619707T3 (es) 2011-09-30 2017-06-26 Dana-Farber Cancer Institute, Inc. Péptidos terapéuticos
WO2013117647A1 (en) * 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
AU2014228502A1 (en) 2013-03-15 2015-08-20 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
JP6518199B6 (ja) * 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
AU2015229009B2 (en) * 2014-03-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring NKG2D pathway function against cancers

Similar Documents

Publication Publication Date Title
JP2018536002A5 (enExample)
JP2020528911A5 (enExample)
Fifis et al. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
JP2019526580A5 (enExample)
JP2006020648A5 (enExample)
JP2016128513A5 (enExample)
JP2019511222A5 (enExample)
PE20181490A1 (es) Tratamientos contra el cancer de utero
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
JP2016516723A5 (enExample)
JP2016539946A5 (enExample)
JP2012501959A5 (enExample)
JP2008530245A5 (enExample)
JP2013543855A5 (enExample)
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
JP2018509163A5 (enExample)
JP2020506690A5 (enExample)
JP2015506179A5 (enExample)
Xiang et al. Promising particle-based vaccines in cancer therapy
JP2019531293A5 (enExample)
JP2012517799A5 (enExample)
JP2014502961A5 (enExample)
JP2012021028A5 (enExample)